Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, is significantly expandin...
Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clini...
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A fina...
German Chancellor Olaf Scholz emphasizes significance for Germany as research location at cornerstone laying ceremony Research center to accelerate biop...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...
EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, announces the successful securing of a t...
Under Narasimhan's leadership, the company sees significant sales and profit growth across major products, prompting an upward revision of the full-year 20...
SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene the...
Johnson & Johnson announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to...
The facilities, located in Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...
“The acquisition of CymaBay brings us a potential best-in-disease therapy that could transform the treatment landscape for people wit...
AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...
© 2025 Biopharma Boardroom. All Rights Reserved.
